Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2
As the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for vaccines to protect individuals at high risk for complications and to potentially control disease outbreaks b...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.784145/full |
| _version_ | 1819282325124415488 |
|---|---|
| author | Marlene Plüß Kemal Mese Johannes T. Kowallick Johannes T. Kowallick Andreas Schuster Andreas Schuster Désirée Tampe Björn Tampe |
| author_facet | Marlene Plüß Kemal Mese Johannes T. Kowallick Johannes T. Kowallick Andreas Schuster Andreas Schuster Désirée Tampe Björn Tampe |
| author_sort | Marlene Plüß |
| collection | DOAJ |
| description | As the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for vaccines to protect individuals at high risk for complications and to potentially control disease outbreaks by herd immunity. Surveillance of rare safety issues related to these vaccines is progressing, since more granular data emerge about adverse events of SARS-CoV-2 vaccines during post-marketing surveillance. Varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation has already been reported in COVID-19 patients. In addition, adverse events after SARS-CoV-2 mRNA vaccination have also been in the context of varicella zoster virus (VZV) reactivation and directly associated with the mRNA vaccine. We present the first case of CMV reactivation and pericarditis in temporal association with SARS-CoV-2 vaccination, particularly adenovirus-based DNA vector vaccine ChAdOx1 nCoV-19 against SARS-CoV-2. After initiation of antiviral therapy with oral valganciclovir, CMV viremia disappeared and clinical symptoms rapidly improved. Since huge vaccination programs are ongoing worldwide, post-marketing surveillance systems must be in place to assess vaccine safety that is important for the detection of any events. In the context of the hundreds of millions of individuals to be vaccinated against SARS-CoV-2, a potential causal association with CMV reactivation may result in a considerable number of cases with potentially severe complications. |
| first_indexed | 2024-12-24T01:13:47Z |
| format | Article |
| id | doaj.art-6b7a5f69ce5243a1823274ce76e86f8b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-24T01:13:47Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6b7a5f69ce5243a1823274ce76e86f8b2022-12-21T17:22:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-01-011210.3389/fimmu.2021.784145784145Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2Marlene Plüß0Kemal Mese1Johannes T. Kowallick2Johannes T. Kowallick3Andreas Schuster4Andreas Schuster5Désirée Tampe6Björn Tampe7Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, GermanyInstitute of Medical Microbiology and Virology, University Medical Center Göttingen, Göttingen, GermanyInstitute of Diagnostic and Interventional Radiology, University Medical Center Göttingen, Göttingen, GermanyGerman Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, GermanyGerman Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, GermanyDepartment of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, GermanyDepartment of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, GermanyDepartment of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, GermanyAs the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for vaccines to protect individuals at high risk for complications and to potentially control disease outbreaks by herd immunity. Surveillance of rare safety issues related to these vaccines is progressing, since more granular data emerge about adverse events of SARS-CoV-2 vaccines during post-marketing surveillance. Varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation has already been reported in COVID-19 patients. In addition, adverse events after SARS-CoV-2 mRNA vaccination have also been in the context of varicella zoster virus (VZV) reactivation and directly associated with the mRNA vaccine. We present the first case of CMV reactivation and pericarditis in temporal association with SARS-CoV-2 vaccination, particularly adenovirus-based DNA vector vaccine ChAdOx1 nCoV-19 against SARS-CoV-2. After initiation of antiviral therapy with oral valganciclovir, CMV viremia disappeared and clinical symptoms rapidly improved. Since huge vaccination programs are ongoing worldwide, post-marketing surveillance systems must be in place to assess vaccine safety that is important for the detection of any events. In the context of the hundreds of millions of individuals to be vaccinated against SARS-CoV-2, a potential causal association with CMV reactivation may result in a considerable number of cases with potentially severe complications.https://www.frontiersin.org/articles/10.3389/fimmu.2021.784145/fullSARS-CoV-2 vaccinationChAdOx1 nCoV-19cytomegalovirusviral reactivationlong COVID |
| spellingShingle | Marlene Plüß Kemal Mese Johannes T. Kowallick Johannes T. Kowallick Andreas Schuster Andreas Schuster Désirée Tampe Björn Tampe Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2 Frontiers in Immunology SARS-CoV-2 vaccination ChAdOx1 nCoV-19 cytomegalovirus viral reactivation long COVID |
| title | Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2 |
| title_full | Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2 |
| title_fullStr | Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2 |
| title_full_unstemmed | Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2 |
| title_short | Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2 |
| title_sort | case report cytomegalovirus reactivation and pericarditis following chadox1 ncov 19 vaccination against sars cov 2 |
| topic | SARS-CoV-2 vaccination ChAdOx1 nCoV-19 cytomegalovirus viral reactivation long COVID |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.784145/full |
| work_keys_str_mv | AT marlenepluß casereportcytomegalovirusreactivationandpericarditisfollowingchadox1ncov19vaccinationagainstsarscov2 AT kemalmese casereportcytomegalovirusreactivationandpericarditisfollowingchadox1ncov19vaccinationagainstsarscov2 AT johannestkowallick casereportcytomegalovirusreactivationandpericarditisfollowingchadox1ncov19vaccinationagainstsarscov2 AT johannestkowallick casereportcytomegalovirusreactivationandpericarditisfollowingchadox1ncov19vaccinationagainstsarscov2 AT andreasschuster casereportcytomegalovirusreactivationandpericarditisfollowingchadox1ncov19vaccinationagainstsarscov2 AT andreasschuster casereportcytomegalovirusreactivationandpericarditisfollowingchadox1ncov19vaccinationagainstsarscov2 AT desireetampe casereportcytomegalovirusreactivationandpericarditisfollowingchadox1ncov19vaccinationagainstsarscov2 AT bjorntampe casereportcytomegalovirusreactivationandpericarditisfollowingchadox1ncov19vaccinationagainstsarscov2 |